ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases
– ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases – Programs will leverage ABL Bio’s Grabody-B platform...
